Home › Chronic Lymphocytic Leukemia › Alabama
Chronic Lymphocytic Leukemia clinical trials in Alabama
7 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Alabama.
Cities in Alabama
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- University of Alabama At Birmingham Hospital, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of Alabama At Birmingham Hospital, Birmingham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- USA Mitchell Cancer Institute ( Site 0014), Mobile
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06136559A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Mitchell Cancer Institute, Mobile
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07218341Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- University of Alabama at Birmingham Cancer Center, Birmingham
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Sep 2, 2026 · NCT07321652HPC Offered for PRESERVE Expansion
- University of Alabama, Birmingham, Birmingham
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Aug 28, 2025 · NCT07145411From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.